Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Other Current Assets · Q4 FY2025 · quarter ended Dec 2025
Other current assets remains negative
Q4 FY2025 other current assets was $0, compared with $0 a year earlier.
Context
- Other current assets amounted to 0.0% of total assets at the end of Q4 FY2025, unchanged from a year earlier.
- Other current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Current Assets vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
- Other current assets amounts to 0.0% of total assets for NNNN, versus a peer median of 2.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $421M USD | +589.5% | +40.3% | 3.2% | |
| Mar 2026 | $25.75M USD | +303.8% | +38.5% | 5.1% | |
| Mar 2026 | $15.97M USD | +45.7% | — | 12.4% | |
| Mar 2026 | CA$15.89M CAD | -20.7% | -14.0% | 1.2% | |
| Mar 2026 | $15.1M USD | +20.8% | -58.7% | 1.4% | |
| Feb 2026 | $13.61M USD | -11.8% | +11.8% | 5.2% | |
| Mar 2026 | $7.71M USD | +175.9% | +69.8% | 1.4% | |
| Mar 2026 | $2.7M USD | +7.0% | -17.9% | 2.0% | |
| Mar 2026 | $2.05M USD | +28.5% | +6.0% | 2.2% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $0 USD | — | — | 0.0% |
| Dec 2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding NNNN) | — | +28.5% | +8.9% | 2.1% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.